PDS Biotechnology Q2 net loss widens slightly as operating costs fall

PDS Biotechnology

13/08/2026 13:39

Overview
US cancer immunotherapy developer's Q2 net loss widened slightly yr/yr
Operating expenses fell due to lower clinical trial and personnel costs
Company will prioritize PDS0301, discontinue internal investment in PDS0101

Outlook
Company to prioritize development of PDS0301 as lead program
PDS Biotech to seek partnerships for continued development of PDS0101

Result Drivers
STRATEGIC REFOCUS - Co prioritized PDS0301 as lead program and discontinued internal investment in PDS0101
LOWER OPERATING EXPENSES - Operating expenses fell due to reduced clinical trial, manufacturing, and personnel costs
HIGHER INTEREST EXPENSES - Net interest expenses rose due to non-cash charge for loss on retirement of debt

Company press release: ID:nGNX9HRlxP

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Loss Per Share
Miss
$0.18
$0.13 (2 Analysts)
Q2 Net Loss
 
$9.80 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for PDS Biotechnology Corp is $4.50, about 1,759.5% above its August 12 closing price of $0.24

Reuters Recommended Reads
Aug 11 - Cardiff Oncology Q2 operating expenses fall on lower R&D costs
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
Aug 11 - Aardvark Therapeutics Q2 operating expenses fall on paused ARD-101 clinical trials and workforce reduction

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)